Hepatitis Test Solution Diagnosis Market Research Report - Global Forecast till 2030

Hepatitis Test Solution Diagnosis Market Research Report Information by Disease Type (Hepatitis A, Hepatitis B, Hepatitis C and others), Type of Technology [Nucleic Acid Testing (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Diagnostic Tests (RDT), Chemiluminescence Immunoassay (CLIA), Genotyping and others], End User (Hospitals, Clinics, Diagnostic Laboratories, Blood Banks, Research Institutes and others) and Region (the Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2030

ID: MRFR/HC/6012-HCR | 110 Pages | Author: Kinjoll Dey | March 2024         

Hepatitis Test Solution Diagnosis Market Speak to Analyst Request a Free Sample

Hepatitis Test Solution Diagnosis Market Scenario


Hepatitis Test Solution Diagnosis Market is expected to grow significantly over the forecast period. It is anticipated that the market held a value of USD 3233.89 Million in 2030 and is projected to register a 3.86% CAGR over the forecast period.


Globally, there are approximately 71 million individuals that are chronically infected with the hepatitis C virus (HCV). The increasing participation of the regulatory agencies and health care associations towards the testing/diagnosis and treatments of the hepatitis is driving the global market. In 2018, the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America, published a guideline for testing, managing, and treating hepatitis C. Various other factors such as the rise prevalence hepatitis, increasing geriatric population, rise in regulatory approvals, and growing participation of generic drugs manufacturers are boosting the market growth.


However, complicated testing and diagnosis process and the side-effects of medication may hamper market growth over the forecast period.


Segmentation


Hepatitis Test Solution Diagnosis Market is segmented based on disease type, type of technology, end user, and region.


Based on disease type, the hepatitis test solution diagnosis market is further segmented into hepatitis A, hepatitis B, hepatitis C, and others.


Based on the type of technology, the hepatitis test solution diagnosis industry at the global level is segmented into nucleic acid testing (NAT), enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests (RDT), chemiluminescence immunoassay (CLIA), genotyping, and others.


Based on end-user, the global market is segmented into hospitals, clinics, diagnostic laboratories, blood banks, research institutes, and others


The segments mentioned above are covered under four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East & Africa.


The hepatitis test solution diagnosis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European hepatitis test solution diagnosis market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The hepatitis test solution diagnosis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The hepatitis test solution diagnosis market in the Middle East & Africa has been segmented into the Middle East and Africa.


Regional Market Summary


Hepatitis Test Solution Diagnosis Market Share (%), by Region, 2018  Hepatitis Test Solution Diagnosis Market


Sources: MRFR Analysis


The Americas dominated the hepatitis test solution diagnosis industry, owing to the increasing number of patients that are diagnosed with hepatitis, annually. In the Latin America and Caribbean countries, currently, around 9 million people are anti-hepatitis C virus (HCV) positive.


Europe is expected to be the second-largest region in the hepatitis test solution diagnosis industry, owing to the growing detection of hepatitis virus cases in the region.


The market in Asia-Pacific (APAC) is expected to grow significantly owing to the rising prevalence of hepatitis genotypes. Various clinical studies are being carried out. For instance, studies related to the Genotype 1b were done to understand the body’s response to the hepatitis virus.


Thus, the hepatitis test solution diagnosis market in APAC is expected to hold the third-largest share during the forecast period.


The Middle East & Africa is expected to hold the least share of the hepatitis test solution diagnosis market during the forecast due to the slow economic development, especially in Africa.


Key Players


Some of the Key Players operating in the Hepatitis Test Solution Diagnosis Market are Abbott, Biomérieux Sa, Bio-Rad Laboratories, Inc., Danaher, DiaSorin S.p.A., Miraca Holdings Inc. (Fujirebio, Inc.), Grifols, Onsite Lab Holding AG (MedMira, Inc.), Qiagen, Roche Holding AG (Roche Diagnostics), Siemens (Siemens Healthineers), and Sandoz International GmbH.


Market Segmentation


Hepatitis Test Solution Diagnosis Market, by Disease Type



  • Hepatitis A

  • Hepatitis B

  • Hepatitis C

  • Others


Hepatitis Test Solution Diagnosis Market, by Type of Technology



  • Nucleic Acid Testing (NAT)

  • Enzyme-Linked Immunosorbent Assay (ELISA)

  • Rapid Diagnostic Tests (RDT)

  • Chemiluminescence Immunoassay (CLIA)

  • Genotyping

  • Others


Hepatitis Test Solution Diagnosis Market, by End User



  • Hospitals

  • Diagnostic Laboratories

  • Blood Banks

  • Research institutes

  • Others


Intended Audience



  • Pharmaceutical companies

  • Government and private laboratories

  • Research and development (R&D) companies

  • Research laboratories

  • Market research and consulting service providers

Report Scope:

Report Attribute/Metric Details
聽聽Market Size 聽聽USD 3233.89 Million (2030)
聽聽CAGR 聽聽3.86% (2022-2030)
聽聽Base Year 聽聽2021
聽聽Forecast Period 聽聽2022-2030
聽聽Historical Data 聽聽2020
聽聽Forecast Units 聽聽Value (USD Million)
聽聽Report Coverage 聽聽Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
聽聽Segments Covered 聽聽disease type, type of technology, end user, and region
聽聽Geographies Covered 聽聽North America, Europe, Asia-Pacific, and Rest of the World (RoW)
聽聽Key Vendors 聽聽Abbott, Biom茅rieux Sa, Bio-Rad Laboratories, Inc., Danaher, DiaSorin S.p.A., Miraca Holdings Inc. (Fujirebio, Inc.), Grifols, Onsite Lab Holding AG (MedMira, Inc.), Qiagen, Roche Holding AG (Roche Diagnostics), Siemens (Siemens Healthineers), and Sandoz International GmbH.
聽聽Key Market Opportunities 路聽 The rise prevalence hepatitis. 路聽 Increasing Geriatric Population. 路聽 Growing participation of generic drugs manufacturers.
聽聽Key Market Drivers 路聽 The increasing participation of the regulatory agencies. 路聽 Health Care associations towards the testing




Frequently Asked Questions (FAQ) :

The market was valued at more than USD 3233.89 million in 2030

The market is expected to exhibit a strong 3.86% CAGR over the forecast period from 2022 to 2030.

The rise in the prevalence of hepatitis is likely to be the major driver for the market.

The Americas hold a dominant share in the global market of more than 45%.

Leading players in the market include Abbott, Miraca, Danaher, and Roche, among others.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players鈥 financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid